Association Between Digoxin Use and Adverse Outcomes Among Patients in the Chinese Atrial Fibrillation Registry
Digoxin is widely used in patients with atrial fibrillation (AF), but its association with adverse outcomes remains controversial.
We aimed to assess the association between digoxin and adverse outcomes in Chinese patients with AF.
We used data from the Chinese Atrial Fibrillation Registry, a prospective, multicenter, hospital-based registry study involving 31 hospitals. In total, 10,472 eligible patients with AF, enrolled from August 2011 to December 2016, were included in this study. The association between digoxin use and all-cause mortality, cardiovascular death, and cardiovascular hospitalization were investigated using Cox proportional hazards models.
In total, 1152 (11%) patients were treated with digoxin at baseline. Patients receiving digoxin were older (mean age 69.7 vs. 66.5 years) and had a higher heart rate (92.4 vs. 79.7 beats/min). A higher proportion of patients receiving digoxin therapy had a history of heart failure (62.5 vs. 15.6%), diabetes mellitus (34.4 vs. 24.4%), and persistent AF (67.9 vs. 38.4%). Digoxin use was independently associated with increased all-cause mortality (adjusted hazard ratio (aHR) 1.21; 95% confidence interval (CI) 1.02–1.43; p = 0.031), cardiovascular death (aHR 1.25; 95% CI 1.01–1.55; p = 0.043), and cardiovascular hospitalization (aHR 1.21; 95% CI 1.05–1.39; p = 0.007). The associations were also homogeneous across various subgroups except in patients with and without renal dysfunction (p value for interaction = 0.029).
In this Chinese AF cohort, for patients who had not undergone ablation, digoxin use was associated with a significant increase in adverse outcomes. Although residual confounders may exist, and serum concentrations of digoxin were unavailable, digoxin should be used with caution in clinical practice, and its effects need to be critically evaluated in randomized trials.
Clinical trial registration
URL: http://www.chictr.org.cn/showproj.aspx?proj=5831. Unique identifier: ChiCTR-OCH-13003729.
Compliance with Ethical Standards
This study complied with standards required for observational study. Ethical approval was obtained from the Human Research Ethics Committees at Beijing Anzhen Hospital. Ethics review boards in each participating hospital approved their participation. Each patient provided informed consent for long-term follow-up.
This study was supported by a Grant (2013BAI09B02) from the Ministry of Science and Technology of the People’s Republic of China and Grants (ZYLX201302, D111100003011004, and D131100002313001) from the Beijing Municipal Commission of Science and Technology.
Conflict of interest
C.-S.M. has received honoraria from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer-Ingelheim (BI) and Bayer for giving lectures. J.-Z.D. has also received honoraria from Johnson & Johnson for giving lectures. G.Y.H.L. is or has been a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, BI, Novartis, Verseon, and Daiichi-Sankyo and a speaker for Bayer, BMS/Pfizer, Medtronic, BI, and Daiichi-Sankyo. YG, SC, XD, XX, and YZ have no conflicts of interest that are directly relevant to the content of this article.
- 2.January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, College American, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;2014(64):e1–76.CrossRefGoogle Scholar
- 3.Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Authors/Task Force Members; Document Reviewers. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–962.CrossRefGoogle Scholar
- 5.Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J. 2013;34:1481–8.CrossRefGoogle Scholar
- 6.Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt S, Holmes TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich PA. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.CrossRefGoogle Scholar
- 12.Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR, ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Lancet. 2015;385:2363–70.CrossRefGoogle Scholar
- 13.Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP. digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017;6(7):e006035.CrossRefGoogle Scholar
- 16.Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K, Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489–97.CrossRefGoogle Scholar
- 17.Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP, ORBIT-AF Investigators. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691–8.CrossRefGoogle Scholar
- 21.Chang SS, Dong JZ, Ma CS, Du X, Wu JH, Tang RB, Xia SJ, Guo XY, Yu RH, Long DY, Bai R, Liu N, Sang CH, Jiang CX, Liu XH, Pan JH, Lip GY. Current status and time trends of oral anticoagulation use among chinese patients with nonvalvular atrial fibrillation: the Chinese Atrial Fibrillation Registry Study. Stroke. 2016;47(7):1803–10.CrossRefGoogle Scholar
- 25.Al-Zakwani I, Panduranga P, Zubaid M, Sulaiman K, Rashed WA, Alsheikh-Ali AA, AlMahmeed W, Shehab A, Al Qudaimi A, Asaad N, Amin H. Impact of digoxin on mortality in patients with atrial fibrillation stratified by heart failure: findings from gulf survey of atrial fibrillation events in the Middle East. J Cardiovasc Pharmacol Ther. 2016;21:273–9.CrossRefGoogle Scholar
- 29.Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A, Dorobantu M, Mercuri M, Lanz H, Rutman H, Wiviott SD, Antman EM, Giugliano RP. Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016;5(7):e003735.CrossRefGoogle Scholar
- 31.Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, Lane DA, La Manna G, Morton J, Mitjans AM, Vos MA, Turakhia MP, Lip GY, Document reviewers. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17(8):1169–96.CrossRefGoogle Scholar
- 32.Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063–74.CrossRefGoogle Scholar
- 35.Chirinos JA, Castrellon A, Zambrano JP, Jimenez JJ, Jy W, Horstman LL, Willens HJ, Castellanos A, Myerburg RJ, Ahn YS. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2:525–9.CrossRefGoogle Scholar
- 36.Pastori D, Carnevale R, Nocella C, Bartimoccia S, Novo M, Cammisotto V, Piconese S, Santulli M, Vasaturo F, Violi F, Pignatelli P. Digoxin and platelet activation in patients with atrial fibrillation: in vivo and in vitro study. J Am Heart Assoc. 2018;7(22):e009509. https://doi.org/10.1161/jaha.118.009509.CrossRefGoogle Scholar